Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes

Japanese Journal of Clinical Oncology

Volumn 35, Issue 6, 2005, Pages 310-315

  Toi, Masakazu ^a   Saeki, Toshiaki ^b,c   Aogi, Kenjiro ^b   Sano, Muneaki ^d   Hatake, Kiyohiko ^e   Asaga, Taro ^f   Tokuda, Yutaka ^g   Mitsuyama, Shoshu ^h   Kimura, Morihiko ⁱ   Kobayashi, Tadashi ^j   Tamura, Motoshi ^k   Tabei, Toshio ^l   Shin, Eisei ^m,n   Nishimura, Reiki ^o   Ohno, Shinji ^p   Takashima, Shigemitsu ^b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^d NIIGATA CANCER CENTER HOSPITAL   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

ⁱ Gunma Cancer Center   (Japan)

^j JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k HOKKAIDO CANCER CENTER   (Japan)

^l SAITAMA CANCER CENTER   (Japan)

^m Department of Orthopaedic Surgery   (Japan)

ⁿ ASTRAZENECA   (United Kingdom)

^o KUMAMOTO CITY HOSPITAL   (Japan)

^p NATIONAL KYUSHU CANCER CENTER   (Japan)

more..

Author keywords

Breast cancer; Chemotherapy; Phase II clinical trials; Vinorelbine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; DOCETAXEL; LIVER ENZYME; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAXOID; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHROPENIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; INFECTION COMPLICATION; INJECTION SITE REACTION; LETHARGY; LEUKOPENIA; MALAISE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHLEBITIS; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME; BREAST TUMOR; DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; REMISSION; TUMOR RECURRENCE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; TAXOIDS; VINBLASTINE;

EID: 23844478319     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi090     Document Type: Article

References (33)

1. Potier P. The synthesis of navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 1989;16(2 Suppl.4):24.
2. Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, et al. Biochemical effect of navelbine on tubulin and associated proteins. Semin Oncol 1989;16(2 Suppl.4):9-14.
3. Kimura M, Ogita M, Morishita Y, Tabei T, Horikoshi N, Nishi T, et al. Late phase II clinical trial of KW-2307 in advanced or recurrent breast cancer. J Jpn Soc Cancer Ther 2001;36:OP-1016 (in Japanese).
4. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52.
5. Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, et al. Phase II trial of weekly vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;5:854-7.
6. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994;12:336-41.
7. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-30.
8. Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, et al. Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. Am J Clin Oncol 1995;18:392-6.
9. Twelves CJ, Dobbs NA, Curnow A, Coleman RE, Stewart AL, Tyrrell CJ, et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994;70:990-3.
10. Terenziani M, Demicheli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, et al. Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996;39:285-91.
11. Vogel C, O'Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999;10:397-402.
12. Winer EP, Morrow M, Osborne CK, Harris JR. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. CANCER. Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott Williams & Wilkins 2001;1699-717.
13. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-400.
14. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267-72.
15. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
16. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-68.
17. Sawada N, Fujimoto-Ouchi K, Ishikawa T, Tanaka Y, Ishitsuka H. Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002;43:5388.
18. Budman DR, Calabro A. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 2002;74:41-6.
19. Kornek GV, Ulrich-Pur H, Penz M, Haider K, Kwasny W, Depisch D, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001;19:621-7.
20. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, et al. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 2000;18:695-701.
21. Romero Acuna L, Langhi M, Perez J, Romero Acuna J, Machiavelli M, Lacava J, et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999;17:74-81.
22. Ellis GK, Gralow JR, Irving Pierce H, Williams MA, Livingston RB. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: High complete response rate in a phase I-II study of doxorubicin-treated patients. J Clin Oncol 1999;17:1407-12.
23. Cohen RB, Mueller SC, Haden K, Souza P. Phase I study on weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer. Cancer Invest 2000;18:422-8.
24. Spano JP, Bouillet T, Boaziz C, Piperno-Neumann S, Brunel P, Hennebelle F, et al. Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. Am J Clin Oncol 2004;27:317-21.
25. Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA, et al. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14: 2993-9.
26. Pronzato P, Queirolo P, Landucci M, Vaira F, Vigani A, Gipponi M, et al. Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. Breast Cancer Res Treat 1997;42:183-6.
27. Campisi C, Fabi A, Papaldo P, Tomao S, Massidda B, Zappala A, et al. Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. Ann Oncol 1998;9:565-7.
28. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51.
29. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000;27(6 Suppl 11):21-25.
30. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30.
31. + metastatic breast cancer. Oncologist 2002;7: 410-7.
32. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95.
33. Suzuki Y, Tokuda Y, Saito Y, Ohta M, Tajima T. Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol 2003;33:514-7.